The successful treatment of mycotic infections in immunosuppressed renal transplant recipients with ketoconazole.
Ketoconazole, a new broad-spectrum antimycotic drug, was administered to six renal transplant recipients with mucocutaneous and/or systemic candidosis. A beneficial clinical and microbiologic effect was seen in the treated patients. This orally administered drug was well tolerated, and side effects were not evident. Our results indicate that good treatment of mycotic infections can be expected even in patients with impaired graft function, since ketoconazole metabolism occurs mainly in the liver.
D000328:Adult; D000935:Antifungal Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D007165:Immunosuppression Therapy / Q000009:adverse effects*; D007654:Ketoconazole; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000188:drug therapy* / Q000209:etiology; D010879:Piperazines / Q000627:therapeutic use*
D000935:Antifungal Agents; D007093:Imidazoles; D010879:Piperazines; D007654:Ketoconazole